The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Five-year monarchE outcome data demonstrate Verzenio’s long-term impact on cancer recurrence in high-risk early breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The phase III monarchE study evaluating two years of adjuvant Verzenio (abemaciclib) in combination with endocrine therapy compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer at a high risk of recurrence demonstrated long-term impact.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan Africa
With help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
By Claire Marie Porter
Cancer Policy

Legislation to increase access to breast and cervical cancer screening introduced in the Senate

Legislation aimed at increasing access to breast and cervical cancer screening was introduced May 22 in the U.S. Senate. The bipartisan Screening for Communities to Receive Early and Equitable Needed Services, or SCREENS, for Cancer Act would reauthorize the National Breast and Cervical Cancer Early Detection Program, or NBCCEDP, for fiscal years 2026 through 2030. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account